SubtlePET’s deep-learning algorithm may result in time savings in PET scanning of up to 75%. Credit: Shutterstock / Image Point Fr.

Melbourne, Australia-based Telix Pharmaceuticals has partnered with Subtle Medical to add the company’s artificial intelligence (AI)-based SubtlePET software to Illuccix, Telix’s imaging agent used in positron emission tomography (PET) scanning for prostate cancer screening.

According to California-based Subtle Medical, SubtlePET’s deep-learning algorithm may result in time savings in PET scanning of up to 75%, with the software able to integrate into existing imaging centre workflows, regardless of PET scanner manufacturer or model.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Illuccix (TLX591-CDx), a radiopharmaceutical imaging agent that uses radioactive isotope Gallium-68, is indicated for PET of prostate-specific membrane antigen (PSMA) in patients with prostate cancer, and gained approval from the US Food and Drug Administration (FDA) in December 2021.

Subtle Medical’s SubtlePET AI software for enhancing PET images, gained CE mark in the EU and 510(k) clearance from the FDA in 2018.

Telix CEO Kevin Richardson commented: “Through this partnership, we are excited to incorporate an innovative AI product into the Illuccix value proposition for our customers and the patients they serve.

“We believe that the combination of Illuccix and SubtlePET will further strengthen Telix’s AI toolkit and also Illuccix’s reputation as the best-in-class PSMA-PET imaging agent for accuracy, reliability, quality, and operational excellence in the US.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData’s Medical Device Intelligence Centre shows that Telix currently has five other products in its pipeline in the indication of prostate cancer.

According to GlobalData analysis, the global PET imaging systems market was valued at around $427m in 2023 and is forecast to reach a valuation of around $547m by 2033, while the Gallium-68-based PET imaging agent market was worth $8.9m in 2023 and is forecast to reach a valuation of $10.5m by 2033.

A 2023 report by GlobalData forecasts that AI platforms across healthcare will reach a global valuation of $18.8bn by 2027.

In 2023, Telix forged a deal with Denmark’s Wiik Pharma to distribute Illuccix across the Nordics and dosed the first patient in the pivotal Phase III registration trial of Illuccix in China, in patients with biochemically recurrent (BCR) prostate cancer.